tirzepatide med New Blockbuster Type 2 Medication Mounjaro Gets FDA Approval China Clears Eli Lilly's Weight

One reviewer shared how timely guidance and side-effect support made the process reassuring and effective

This data-driven approach helps you and your provider decide whether to extend, adjust, or transition your therapy with confidence

Our editors independently choose our recommendations

Early phase trials in T2DM indicate that tirzepatide improves clinical outcomes beyond those achieved by a selective GLP-1 receptor agonist

The Phase 3 ENLIGHTEN-Fibrosis trial in non-cirrhotic (F2-F3) MASH and Phase 3 ENLIGHTEN-Cirrhos is trial in compensated cirrhotic (F4) MASH continue to enroll patients, with topline data from the histology cohorts of these trials expected in the first half of 2027 and in 2028, respectively